A5513
N-Acetylprocainamide hydrochloride
≥99% (HPLC), powder
Sinonimo/i:
N-Acetylnovocainamide hydrochloride, Acecainide hydrochloride, NAPA
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Formula condensata:
4-(CH3CONH)C6H4CONHCH2CH2N(C2H5)2·HCl
Numero CAS:
Peso molecolare:
313.82
Numero CE:
Numero MDL:
Codice UNSPSC:
12352100
ID PubChem:
NACRES:
NA.77
Prodotti consigliati
Livello qualitativo
Saggio
≥99% (HPLC)
Stato
powder
Punto di fusione
184-186 °C (lit.)
Solubilità
H2O: 50 mg/mL
Temperatura di conservazione
−20°C
Stringa SMILE
Cl[H].CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1
InChI
1S/C15H23N3O2.ClH/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19;/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19);1H
IYEWBJUCJHKLHD-UHFFFAOYSA-N
Cerchi prodotti simili? Visita Guida al confronto tra prodotti
Applicazioni
N-Acetylprocainamide hydrochloride may be used:
- as an internal standard for spiking plasma samples for ultra-high-pressure liquid chromatography coupled with a diode array detector (UHPLC-DAD) analysis
- to test its relaxant effect on tracheal smooth muscle tissue preparations
- in preparation of complexes with N-acetyl-L-tyrosine methyl ester and N-acetyl-L-phenylalanine methyl ester for studying intermolecular interactions using nuclear magnetic resonance (NMR) spectroscopy studies
N-Acetylprocainamide hydrochloride is a class III antiarrhythmic compound. N-Acetylprocainamide hydrochloride has been used in a study to determine the disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition. N-Acetylprocainamide hydrochloride has also been used to study pharmacokinetics of procainamide and N-acetylprocainamide in rats.
Azioni biochim/fisiol
N-acetyltransferase II in liver catalyzes the conversion of procainamide to N-acetylprocainamide (NAPA).
Class III antiarrhythmic. Increases the duration of the action potential by decreasing the delayed outward potassium current, slightly decreasing the calcium current, and slightly depressing the inward rectifier potassium current. This is the active metabolite of procainamide that does not induce systemic lupus erythematosus.
Codice della classe di stoccaggio
11 - Combustible Solids
Classe di pericolosità dell'acqua (WGK)
WGK 3
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Dispositivi di protezione individuale
Eyeshields, Gloves, type N95 (US)
Scegli una delle versioni più recenti:
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
I clienti hanno visto anche
B L Kamath et al.
Journal of pharmaceutical sciences, 70(3), 299-302 (1981-03-01)
The pharmacokinetics of distribution and elimination of procainamide and its major metabolite, N-actylprocainamide, were studied in rats. Eight rats were selected randomly, and each received intravenously 14C-labeled procainamide hydrochloride (75 mg/kg) or 14C-labeled N-acetylprocainamide hydrochloride (86 mg/kg) according to a
D Jung et al.
Drug metabolism and disposition: the biological fate of chemicals, 13(3), 359-363 (1985-05-01)
The influence of dietary protein deficiency on the disposition of procainamide (PA) and its major metabolite, N-acetylprocainamide (NAPA) was investigated in male Sprague-Dawley rats fed for 4 weeks on a 23 (control) or a 5% (low) protein diet ad libitum.
The evidence for complex formation between N-acetyl-l-tyrosine methyl ester and N-acetylprocainamide hydrochloride using NMR spectroscopy
Janik A, et al.
Structural Chemistry, 20(4), 699-707 (2009)
Larry A Bauer et al.
Antimicrobial agents and chemotherapy, 49(4), 1649-1651 (2005-03-29)
Ten healthy adults participated in a randomized, crossover drug interaction study testing procainamide only, procainamide plus levofloxacin, and procainamide plus ciprofloxacin. During levofloxacin therapy, most procainamide and N-acetylprocainamide (NAPA) pharmacokinetic parameters, including decreased renal clearances and renal clearance/creatinine clearance ratios
M Boucher et al.
Journal of autonomic pharmacology, 18(2), 83-87 (1998-09-08)
1. The cardiac anticholinergic effects of procainamide (1 mg kg(-1) min(-1)) and its N-acetylated metabolite (NAPA) at equimolar dose (1.16 mg kg(-1) min(-1)) were studied using in vivo experimental pharmacological and in vitro radioligand binding studies. 2. Procainamide and NAPA
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.